Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells
暂无分享,去创建一个
R. Oostendorp | C. Peschel | T. Decker | F. Schneller | I. Ringshausen | L. Quintanilla‐Martinez | C. Bogner | F. Fend | G. Häcker | K. Goetze
[1] R. Millikan,et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Campo,et al. variants of mantle cell lymphoma (MCL): implications for pathogenesis Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic , 2013 .
[3] Beverly S Mitchell,et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] X. Zhang,et al. Ubiquitin/Proteasome-dependent Degradation of D-type Cyclins Is Linked to Tumor Necrosis Factor-induced Cell Cycle Arrest* , 2002, The Journal of Biological Chemistry.
[5] JB Almond,et al. The proteasome: a novel target for cancer chemotherapy , 2002, Leukemia.
[6] J. Gribben,et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Manfredi,et al. Multiple roles of the tumor suppressor p53 , 2002, Current opinion in oncology.
[8] B. Branger,et al. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype , 2001, Leukemia.
[9] I. Herr,et al. Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.
[10] R. Heilig,et al. A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia , 2001, Leukemia.
[11] H. Hoefler,et al. p27Kip1 Immunostaining for the Differential Diagnosis of Small B-Cell Neoplasms in Trephine Bone Marrow Biopsies , 2001, Modern Pathology.
[12] A. Hunter,et al. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex , 2001, Leukemia.
[13] J. Leonard,et al. Biology and management of mantle cell lymphoma , 2001, Current opinion in oncology.
[14] P. R. Yew,et al. Ubiquitin‐mediated proteolysis of vertebrate G1‐ and S‐phase regulators , 2001, Journal of cellular physiology.
[15] P. Elliott,et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.
[16] M. Vu,et al. Proteasomes Modulate Balance Among Proapoptotic and Antiapoptotic Bcl-2 Family Members and Compromise Functioning of the Electron Transport Chain in Leukemic Cells1 , 2001, The Journal of Immunology.
[17] S-G Hwang,et al. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition , 2000, Leukemia.
[18] S. Ōmura,et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. , 2000, Blood.
[19] Shigeo Nakamura,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma , 2000 .
[20] M. Seto,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.
[21] W. Telford,et al. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4 , 2000, Leukemia.
[22] M Chilosi,et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. , 2000, Blood.
[23] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] S Omura,et al. Increased sensitivity of CLL‐derived lymphocytes to apoptotic death activation by the proteasome‐specific inhibitor lactacystin , 1999, British journal of haematology.
[25] E. Sausville,et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.
[26] M. Grever,et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. , 1998, Cancer research.
[27] P. Guldberg,et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb , 1998, Leukemia.
[28] Sanjeev Sharma,et al. A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. , 1998, Journal of immunology.
[29] E. Campo,et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. , 1998, The American journal of pathology.
[30] S. Schreiber,et al. Lactacystin, Proteasome Function, and Cell Fate* , 1998, The Journal of Biological Chemistry.
[31] H. Müller-Hermelink,et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. , 1997, Blood.
[32] H. Drexler. Activation of the cell death program by inhibition of proteasome function. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] C. Sherr. Cancer Cell Cycles , 1996, Science.
[34] N. Harris,et al. Expression of the Retinoblastoma Protein in Low-Grade B-Cell Lymphoma: Relationship to Cyclin D1 , 1996 .
[35] W. Chan,et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. , 1996, Blood.
[36] P. Beer-Romero,et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. , 1995, Science.
[37] H. Koeffler,et al. Role of the cyclin-dependent kinase inhibitors in the development of cancer. , 1995, Blood.
[38] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[39] C. M. Steel,et al. Characterization of a new non-Hodgkin's lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. , 1988, Blood.
[40] G. Cohen,et al. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. , 2001, Leukemia.
[41] M. Seto,et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. , 2000, Blood.
[42] W. Baumeister,et al. The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.
[43] J. Gribben,et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Campo,et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. , 1997, Blood.
[45] J. Bartek,et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519) , 1997, Leukemia.
[46] N. Harris,et al. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: relationship to cyclin D1. , 1996, Blood.
[47] A. López-Guillermo,et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. , 1994, Blood.